van Kammen DP - Search Results

1

Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures.

Yao JK, van Kammen DP, Gurklis J. Yao JK, et al. Among authors: van kammen dp. Schizophr Res. 1994 Oct;13(3):227-32. doi: 10.1016/0920-9964(94)90046-9. Schizophr Res. 1994. PMID: 7841135

2

The effects of antipsychotic medication on factor and cluster structure of neurologic examination abnormalities in schizophrenia.

Goldstein G, Sanders RD, Forman SD, Tarpey T, Gurklis JA, Van Kammen DP, Keshavan MS. Goldstein G, et al. Among authors: van kammen dp. Schizophr Res. 2005 Jun 1;75(1):55-64. doi: 10.1016/j.schres.2004.08.016. Schizophr Res. 2005. PMID: 15820324 Clinical Trial.

3

Semantic memory in schizophrenia: association with cell membrane essential fatty acids.

Condray R, Yao JK, Steinhauer SR, van Kammen DP, Reddy RD, Morrow LA. Condray R, et al. Among authors: van kammen dp. Schizophr Res. 2008 Nov;106(1):13-28. doi: 10.1016/j.schres.2008.03.009. Epub 2008 Oct 16. Schizophr Res. 2008. PMID: 18929465 Free PMC article.

4

Membrane phospholipids and cytokine interaction in schizophrenia.

Yao JK, van Kammen DP. Yao JK, et al. Among authors: van kammen dp. Int Rev Neurobiol. 2004;59:297-326. doi: 10.1016/S0074-7742(04)59012-8. Int Rev Neurobiol. 2004. PMID: 15006493 Review.

5

CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.

van Kammen DP, Peters J, Yao J, Neylan T, Beuger M, Pontius E, O'Connor DT. van Kammen DP, et al. Schizophr Res. 1991 Dec;6(1):31-9. doi: 10.1016/0920-9964(91)90018-m. Schizophr Res. 1991. PMID: 1723893

6

Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures.

Peters J, Van Kammen DP, Gelernter J, Yao J, Shaw D. Peters J, et al. Among authors: van kammen dp. Schizophr Res. 1990 Oct-Dec;3(5-6):287-94. doi: 10.1016/0920-9964(90)90012-v. Schizophr Res. 1990. PMID: 2178001

7

Clonidine treatment of schizophrenia: can we predict treatment response?

van Kammen DP, Peters JL, van Kammen WB, Rosen J, Yao JK, McAdam D, Linnoila M. van Kammen DP, et al. Among authors: van kammen wb. Psychiatry Res. 1989 Mar;27(3):297-311. doi: 10.1016/0165-1781(89)90145-5. Psychiatry Res. 1989. PMID: 2469097 Clinical Trial.

8

Polyunsaturated fatty acids, prostaglandins, and schizophrenia.

van Kammen DP, Yao JK, Goetz K. van Kammen DP, et al. Ann N Y Acad Sci. 1989;559:411-23. doi: 10.1111/j.1749-6632.1989.tb22626.x. Ann N Y Acad Sci. 1989. PMID: 2672945 Review.

9

Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.

van Kammen DP, Agren H, Yao JK, O'Connor DT, Gurklis J, Peters JL. van Kammen DP, et al. Am J Psychiatry. 1994 Mar;151(3):379-84. doi: 10.1176/ajp.151.3.379. Am J Psychiatry. 1994. PMID: 7509126

10

Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.

van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Peters JL. van Kammen DP, et al. Arch Gen Psychiatry. 1995 Aug;52(8):673-8. doi: 10.1001/archpsyc.1995.03950200063015. Arch Gen Psychiatry. 1995. PMID: 7543265

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

241 results

Search Page

Filters